SNTI News and Press, Senti Biosciences Inc. From 09/30/22

3 Penny Stocks to Watch as the Stock Market Remains Volatile Investing in penny stocks can be a great way to build your wealth over time. But it’s not without its risks. Before you decide to buy penny stocks, it’s important to understand the potential rewards and risks inv...

Why The Stock Market Is Down Today But wait, the stock market crash is over. At least, that is what some retail traders thought after yesterday’s broad-sector bounce led by tech. Waking up to the stock market today painted a much different picture. Even with this as the case, in ...

Chardan Capital Markets has initiated Senti Biosciences ( NASDAQ: SNTI ) with a buy highlighting the potential of the company's gene circuit synthetic biology platform and engineered cell therapy pipeline. The firm says the platform and pipeline can "address several l...

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that co-founder and CEO...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com We’re starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning! Moving stocks this morning is an acquisition deal, an update from ...

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that co-founder and CEO...

Chardan Announces Launch of ChEF (Chardan Equity Facility) PR Newswire NEW YORK , Sept. 1, 2022 /PRNewswire/ -- Chardan, a global investment bank, has announced the launch of its Chardan Equity Facility (ChEF) product, an innovative financing solution used t...

SOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that on August 18, 2022,...

Senti Biosciences press release ( NASDAQ: SNTI ): Q2 GAAP EPS of -$0.86. Revenue of $1.36M (+72.2% Y/Y). As of June 30, 2022, Senti Bio held cash and cash equivalents of $139.8M, which the company believes is sufficient to fund operations into 2024. For further d...

- Lead development candidate selected from SENTI-202 program; on track for IND filing in 2023 - - Expect to present CAR-NK cell therapy program data at multiple scientific conferences in 2022 - - Cash position of $139.8 million as of June 30, 2022 expected to fund curren...